Lantheus Holdings to Acquire Evergreen Theragnostics for $250 Million Upfront
January 28, 2025
Lantheus Holdings has signed a definitive agreement to acquire Evergreen Theragnostics in an all-cash deal with a $250 million upfront payment and up to $752.5 million in development and sales milestones. The acquisition is intended to expand Lantheus into a fully integrated radiopharmaceutical leader by adding Evergreen’s radiopharmaceutical CDMO manufacturing infrastructure and development capabilities, as well as the registrational-stage PET diagnostic agent OCTEVY.
- Buyers
- Lantheus Holdings, Inc.
- Targets
- Evergreen Theragnostics, Inc.
- Industry
- Healthcare Services
- Location
- New Jersey, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Lantheus Acquires Life Molecular Imaging (Life Molecular) for $350M Upfront
July 22, 2025
Healthcare Services
Lantheus Holdings completed its previously announced acquisition of Life Molecular Imaging Ltd., a subsidiary of Life Healthcare Group Holdings Ltd. The deal includes an upfront payment of $350 million and (per the earlier definitive agreement) up to $400 million in potential earn-out and milestone payments, and strengthens Lantheus’s commercial and R&D capabilities in Alzheimer’s PET diagnostics with Neuraceq (florbetaben F18).
-
SHINE Technologies Completes Acquisition of Lantheus SPECT Business
January 2, 2026
Healthcare Services
SHINE Technologies completed its acquisition of Lantheus’ SPECT business, including the North Billerica, Massachusetts manufacturing facility and the diagnostic radiopharmaceutical product portfolio. The deal expands SHINE’s nuclear medicine platform with established SPECT production expertise and market relationships, positioning SHINE to strengthen the medical isotope supply chain for diagnostic imaging.
-
Novartis Acquires Mariana Oncology
May 2, 2024
Biotechnology
Novartis will acquire Mariana Oncology for $1 billion upfront and up to $750 million in milestone payments, bringing Mariana's peptide-based radiopharmaceutical pipeline and manufacturing capabilities into Novartis. The deal adds radioligand therapeutic discovery, isotope supply chain and manufacturing know-how to Novartis to accelerate development and commercialization of targeted cancer therapies.
-
Ariceum Therapeutics Acquires Theragnostics Ltd.
June 1, 2023
Biotechnology
Ariceum Therapeutics has acquired 100% of Theragnostics Ltd., a UK-based developer of radiopharmaceutical diagnostic and therapeutic products, for $2.5 million upfront plus up to $41.5 million of milestone payments. The deal gives Ariceum late preclinical/early clinical PARP inhibitor assets, US FDA‑approved NEPHROSCAN™ (partnered with GE Healthcare) and expanded US operations, strengthening its diagnostic and therapeutic radiopharmaceutical pipeline.
-
Lantheus Holdings Acquires Cerveau Technologies
February 6, 2023
Pharmaceuticals
Lantheus Holdings, Inc. acquired Knoxville-based Cerveau Technologies, Inc., gaining MK-6240, a clinical-stage F-18 PET imaging agent that targets Tau tangles in Alzheimer's disease. The stock purchase includes upfront and potential milestone payments plus royalty obligations and will expand Lantheus' radiopharmaceutical diagnostic imaging pipeline and research collaborations.
-
Lantheus Acquires Meilleur Technologies (NAV-4694)
July 15, 2024
Pharmaceuticals
Lantheus Holdings, Inc. announced the acquisition of Meilleur Technologies, Inc., giving Lantheus worldwide exclusive rights to NAV-4694 (F18-flutafuranol), a Phase 3 ß-amyloid PET imaging agent for Alzheimer’s disease. The deal includes an upfront payment plus potential development/commercial milestones and royalties, and the sellers will provide transition and clinical development services following closing.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.